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Abstract 
Introduction. Body dysmorphic disorder (BDD) is a debilitating disorder, characterised by 
obsessions and compulsions relating specifically to perceived appearance, newly classified within 
the DSM-5 Obsessive-Compulsive and Related Disorders grouping. Until now, little research has 
been conducted into the cognitive profile of this disorder.  
Methods. Participants with BDD (n=12) and participants without BDD (n=16) were tested using a 
computerised neurocognitive battery investigating attentional set-shifting (Intra/Extra Dimensional 
Set Shift Task), decision-making (Cambridge Gamble Task), motor response-inhibition (Stop-Signal 
Reaction Time Task) and affective processing (Affective Go-No Go Task). The groups were 
matched for age, IQ and education. 
Results. In comparison to controls, patients with BDD showed significantly impaired attentional set 
shifting, abnormal decision-making, impaired response inhibition and greater omission and 
commission errors on the emotional processing task.  
Conclusion. Despite the modest sample size, our results showed that individuals with BDD 
performed poorly compared to healthy controls on tests of cognitive flexibility, reward and motor 
impulsivity and affective processing. Results from separate studies in OCD patients suggest similar 
cognitive dysfunction. Therefore, these findings are consistent with the re-classification of BDD 
alongside OCD. These data also hint at additional areas of decision-making abnormalities that might 
contribute specifically to the psychopathology of BDD. 
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Introduction 
 
Individuals with Body Dysmorphic Disorder (BDD) are troubled by intrusive thoughts that they 
have a bodily imperfection that is visibly unsightly 1. In some cases, they have a minor physical flaw 
that would not be regarded as abnormal or noticeable by most people; in other cases, the defect is 
imaginary. They fear showing the ‘imperfection’ in public 2,  leading to social avoidance and 
isolation. They spend considerable time ruminating about the perceived defect, and engage in time 
consuming checking, camouflaging and reassurance-seeking rituals 3.   
 
BDD has been relatively neglected by research, perhaps in part due to the assumption that it is a rare 
condition. However, extant epidemiological data contradict this perspective.  In a German sample of 
approximately 2500 individuals, selected to be representative of the general population, the point 
prevalence of BDD was estimated at 1.2-2.1% 4. In a national household telephone survey conducted 
in approximately 2000 US citizens, the point prevalence was estimated at 2.4% 5. Other studies, 
mostly conducted in college student samples, suggest a point prevalence rate of around 2.5% or 
greater 6-9. In addition to being relatively common, BDD is associated with profound impairment in 
quality of life and everyday functioning 5. Insight is frequently impaired and treatment-adherence is 
noted to be poor 10. Furthermore, a prospective study conducted over four years in 185 subjects with 
BDD indicates that suicidality is a major concern. Each year, suicidal ideation occurred in more than 
50% of individuals with BDD, 2.6% attempted suicide, and 0.3% completed suicide 11.   
 
Anorexia nervosa (AN- restricting food) and bulimia nervosa (BN- binging and vomiting) are 
examples of eating disorders that are also associated with abnormal body image concerns and 
subjects with both these disorders have been shown to demonstrate a greater avoidance of their own 
image and negative self-evaluation than healthy controls 12. Studies have demonstrated co-morbid 
and familial overlap between eating disorder, OCD and BDD 13,14. In people with OCD, co-morbid 
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BDD has been reported in up to 37% of cases 15. In patients with eating disorder (including both AN 
and BN), up to 45% have been found to show comorbid BDD 16,17. Furthermore, in a seminal OCD 
family study, the first-degree relatives of OCD patients were at significantly elevated risk 
specifically for BDD, eating disorders grooming disorder and hypochondriasis, as compared to 
control relatives14. These findings are suggestive of a familial overlap between BDD and OCD on 
the one hand, a fact supported by previous reviews of age of onset, personality characteristics and 
course of illness18 and similar cognitive deficits, such as set shifting19 found in those with AN and 
BN. 
 
In recognition of its nosological status as a compulsive disorder, the DSM-5 has moved BDD into 
the same category as obsessive compulsive disorder (OCD), under an expanded grouping of 
Obsessive Compulsive and Related Disorders American Psychiatric Association, 20. Studies have 
demonstrated co-morbid and familial overlap between OCD and BDD 13. In those with OCD, co-
morbid BDD has been reported in up to 37% of cases 15. Furthermore, in two seminal OCD family 
studies, the first-degree relatives of OCD probands were at significantly elevated risk for BDD, as 
well as trichotillomania, skin picking disorder and hypochondriasis, as compared to control relatives 
Bienvenu et al., 14,Bienvenu et al., 21. These findings are suggestive of a familial overlap between 
BDD and OCD on the one hand and between BDD and other putative obsessive compulsive and 
related disorders on the other, perhaps mediated by common genetic and/or cognitive predisposing 
factors.  
 
Understanding of the neurobiology of BDD and related conditions may be informed by the use of 
cognitive tests that are dependent on the integrity of frontal lobe functioning. Various cognitive 
impairments have been identified in OCD using computerised paradigms from the Cambridge 
Neuropsychological Test Automated Battery (CANTAB www.cambridgecognition.com), including 
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in the domains of set-shifting (Extra-Dimensional Set-Shift (EDS)), inhibitory motor control (Stop-
Signal Reaction Time (SSRT)), executive planning (Stockings of Cambridge (SOC) test), and 
affective bias toward negatively-valenced stimuli (for reviews see 22-24).’ These outcome measures 
can fractionate broad cognitive processes into constituent domains, and can be linked with different 
neural substrates25; they have been used in translational research across species26,27, as well as in 
people with focal neurosurgical lesions, and in acute drug manipulations. This background validation 
is of value in interpreting new cognitive findings in conditions such as BDD. For some deficits 
(Extra-Dimensional Set-Shift, Stop-Signal Reaction Time, Stockings of Cambridge), similar 
cognitive dysfunction exists in unaffected first-degree relatives of patients with OCD and these 
therefore may represent predisposing or ‘vulnerability’ markers (e.g. 28-30). The findings are broadly 
consistent with current neurobiological models of OCD, which implicate not only dysfunction within 
the classical orbitofrontal circuitry but also the dorsolateral prefrontal cortical circuitry, which 
incorporate these cortical regions but also subcortical nodes including the ventral and dorsal striatum 
23,31. 
 
There have been few published studies exploring neuropsychological function in BDD.  Hanes and 
colleagues compared 14 subjects with BDD with 10 subjects with OCD and 24 controls, using a 
variety of non-computerised tests 32. Both the BDD and OCD groups were similarly impaired, 
compared to controls, on tests of executive planning (Tower of London task) and colour-word 
interference (Stroop task), supporting the hypothesis that these two conditions are neurobiologically 
related. No significant deficits emerged in the BDD or OCD groups for category fluency and motor 
skill/speed on the Purdue Pegboard task, verbal learning on the Rey Auditory Verbal Learning task, 
or non-verbal learning/memory function on the Rey Complex Figures task (RCFT). In contrast, 
another study 33, again using non-computerised tests, identified impairment in non-verbal 
learning/mnemonic domains (Rey Complex Figures Task), along with verbal learning impairment 
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(California Verbal Learning Test), in 17 patients with BDD compared to 17 healthy controls. The 
authors postulated that the deficits were mediated by poor organisational strategy. Dunai and 
colleagues 34 additionally explored cognitive functioning in 14 patients with BDD versus 14 healthy 
controls, using selected computerised paradigms from the CANTAB. Patients with BDD were 
impaired on spatial working memory (Spatial Working Memory test) and executive planning (SOC 
test); findings similar to those reported separately for OCD 35. In a more recent study, executive 
dysfunction was investigated in 14 BDD participants, 14 matched (age and gender) healthy controls, 
and 23 participants with OCD. Similarities were seen in the BDD and OCD groups in spatial span, 
spatial working memory, pattern recognition and spatial planning (SOC) tasks compared with 
healthy controls. However, those with BDD were found to have relatively greater deficits in 
executive functioning, on the accuracy measure of the SOC Task, than those with OCD and 
compared with healthy controls 36. A recent study found similarities between BDD and OCD groups 
on measures of attention and memory, compared with controls 37. Toh and colleagues used the 
Repeated Battery for the Assessment of Neuropsychological Status (RBANS), which assesses broad 
domains of memory, attention and visuospatial skills and benefits from the use of a healthy control 
group in the comparison of BDD and OCD samples. Their results showed some evidence of 
similarity in broad cognitive processing impairment that is unlikely to be disease specific. The study 
merits further exploration with tasks of greater neural specificity and robust evidence of impairment 
in OCD. The study offers further credibility to the idea that BDD falls within obsessive-compulsive 
spectrum disorders.  
 
Based on the above limited evidence, the current study sought to explore specific aspects of 
cognitive functioning in BDD and healthy volunteers using relevant tests from the CANTAB. We 
focused on motor response inhibition (using the SSRT), cognitive flexibility (using the Intra-Extra 
Dimensional (IED) Set Shifting Task), and affective processing using the Affective Go/NoGo task 
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(AGN). These three cognitive domains are linked to behavioural inhibition and have not previously 
been investigated in BDD, but have been found to be impaired in non-comorbid OCD. For example, 
Kerwin et al., 38 found deficits in global and local processing, visual processing and cognitive 
flexibility in un-medicated individuals with BDD compared with non-clinical controls. These 
deficits were greater in those with more severe illness with poor insight and the finding merit further 
research to ascertain whether these areas serve to maintain BDD symptoms. 
 
We also included a test of decision-making (Cambridge Gambling Task- CGT), which tests aspects 
of reward-based impulse control, and which has previously been observed to be intact in OCD 35, but 
which is impaired in patients with behavioural and substance addiction 24,39. It was hypothesised that 
BDD would be associated with a similar cognitive profile to that previously reported in OCD: 
namely, significantly impaired response inhibition and set-shifting, evidence of affective bias with 
increased sensitivity to negatively-valenced cues, but intact decision-making.  
 
 
 
Materials and Methods 
 
Participants 
BDD patients, aged between 18 and 65 years of age, were recruited from the specialist OCD/BDD 
outpatient clinic of one of the authors (NAF).  All had a DSM-IV diagnosis of BDD, ascertained by 
a semi-structured diagnostic interview by a consultant psychiatrist and a detailed clinical assessment 
amplified by the Yale Brown Obsessive Compulsive Checklist and Scale for Body Dysmorphic 
Disorder (BDD-YBOCS) 40 to determine the degree of illness severity. In order to meet the inclusion 
criteria for the study, BDD was required to constitute the primary illness. All psychiatric 
 8 
comorbidity (such as OCD) as documented in the case notes was recorded. Healthy controls were 
recruited from a non-treatment seeking population via the University of Hertfordshire email 
recruitment system. In order to meet the inclusion criteria for the study, healthy controls must not 
have a diagnosis of BDD or any other other primary illness. Illness symptomatology was measured 
using the BDD-YBOCS, Montgomery-Asberg Depression Rating Scale (MADRS) and the Hamilton 
Anxiety Scale (HAM-A). 
 
Demographic analysis 
Twelve individuals with BDD (mean duration of illness 133.5 months [11.13 years]) and 16 healthy 
individuals without BDD (controls) completed cognitive tasks and clinical questionnaires (Table 1). 
Importantly, the two groups did not differ significantly with regard to age, education and estimated 
IQ using the National Adult Reading Test 41 see Table 1).  
 
Table one about here 
 
Age, IQ and education-matched control participants without a diagnosis of BDD were recruited from 
the University of Hertfordshire. Control participants were approached via speaking to individuals on 
the University premises or via the university’s SONA system (an online computerised system by 
which students can indicate their interest in participating in research studies).  Participants were 
requested to be without Body Dysmorphic Disorder and were screened to exclude the presence of 
the disorder symptoms using the BDD-YBOCS using a cut off of >10. None of the participants in 
the control group scored more than 10 on this clinical rating scale. 
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Clinical measures 
Severities of depression and anxiety symptoms were quantified in all participants using the 
Montgomery-Åsberg Depression Rating Scale 42 and the Hamilton Anxiety Scale 43. 
 
Neuropsychological Measures 
Participants completed the following paradigms from the CANTAB - see below. The tasks were 
administered in a fixed order (as below), in a quiet testing environment, supervised by a trained test 
administrator.  
 
The intra/extra dimensional set-shift task (IED- http://www.cambridgecognition.com/tests/intra-
extra-dimensional-set-shift-ied)  
This is a nine-stage visual discrimination task and measures cognitive flexibility 44 in which two 
stimuli are presented at a time and participants ascertain, by computerised feedback, which of the 
stimuli is correct, and thus, the ‘rule’ of the game. Following six consecutive indications of the 
correct stimulus the ‘rule’ alters.  The extra dimensional shift (EDS) stage of the task is crucial for 
determining divergent thinking deficits as the participant is required to shift their attentional focus 
from the previously relevant stimulus dimension to a previously irrelevant stimulus dimension.  Such 
set-shifting depends on the ventrolateral prefrontal cortex 45. The outcome measures of interest on 
this task include the total number of errors and total number of stages successfully completed.  
 
The Cambridge Gambling Task (CGT- http://www.cambridgecognition.com/tests/cambridge-
gambling-task-cgt)  
This task assesses dissociable aspects of decision-making. Participants are asked to accumulate as 
many points as they can by making gambles across a range of different winning probabilities. Each 
trial has differing proportions of red and blue boxes from which participants are asked to place a bet 
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on the location of a yellow token  based on their confidence in their choice. The bet amount either 
increases incrementally  (5%, 25%, 50%, 75%, 95% of total collected points) or decreases (reverse 
order) over time. Outcome measures include mean percentage of points gambled (total proportion of 
overall bets), quality of decision-making (this measures rational decision making and is measured by 
the calculating the proportion of trials where the participant chose the more likely outcome (box 
colour), risk taking (the mean proportion of points bet on trials where the most likely outcome was 
chosen), deliberation time (how long it took to decide on which bet to choose) and delay aversion; 
this is measured as the tendency for participants to bet larger amounts due to an unwillingness, or 
inability, to wait for bets to decrease on trials where bet amounts are presented in descending order 
compared with when bets are presented in ascending order.  
 
The Stop Signal Task (SST- http://www.cambridgecognition.com/tests/stop-signal-task-sst)  
This is a measure of pre-potent motor inhibition. Participants are required to respond rapidly to left 
or right oriented arrows, presented on a blank screen. When an audible sound emits (the ‘stop-
signal’) from the task screen, participants are required to inhibit their response for that arrow and 
their degree of success is measured. Over the course of the test, the time between the presentation of 
the ‘go’ stimulus and the ‘stop-signal’ varies using a tracking algorithm. The main outcome measure 
on the task is the Stop-Signal Reaction Time (SSRT), which is an estimate of the time taken by the 
given individual to stop or suppress a response that would ordinarily be undertaken; longer SSRTs 
equate to poorer motor response inhibition, or greater ‘motor impulsivity’. The other outcome 
measure of interest is the median reaction time for ‘go’ trials; a generic measure of response speed 
not relating to inhibitory control.  
 
The Affective Go/NoGo (AGN- http://www.cambridgecognition.com/tests/affective-go-no-go-agn) 
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This task assesses mood processing bias.  A series of positive and negative words are presented on 
screen. The participant is required to respond to predetermined ‘target’ words by pressing a key pad 
when they see a target word. This target word will be ‘positive’ or ‘negative’ in valence. Other non-
affective words are considered ‘distractor’ words and participants are required to avoid responding 
to these words and to only respond to the ‘target’ word. The outcome variables of interest include the 
mean correct latency representing the length of time each participant takes to respond to target 
words, as well as the total number of commission errors (pressing for a positive target word when it 
is a negative one or vice-versa) and omission errors (failing to respond when one should have done 
so).  
 
Statistical analysis 
Between-group differences were investigated by conducting a multivariate Analysis of Variance 
(MANOVA) using IBM SPSS. Further exploratory analysis in SPSS included a test of covariance 
using anxiety (Ham-A) and depression (MADRS) scores as covariates. This being an exploratory 
study, statistical significance was defined as p<0.05 uncorrected.  
 
Results 
 
Clinical analysis  
The BDD group showed a range of symptom-severity ranging from mild to moderately severe 
(BDD-YBOCS total range 7-24). The mean BDD Y-BOCS was 13.25 (SD 4.88), representing mild 
BDD. Control BDD-YBOCS scores ranged from 0-10 with an average score of 2.38 (SD= 3.40). 
None of the 16 control participants were taking prescribed medication, while all 12 of the BDD 
participants were taking prescribed medication (2 citalopram, 6 escitalopram, 3 fluvoxamine and 1 
sertraline). Nine of the twelve BDD patients expressed symptoms of comorbid OCD. Two of the 
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nine were also diagnosed with comorbid social anxiety disorder and one patient was diagnosed with 
gender dysphoria (DSM-5), previously Gender Identity Disorder American Psychiatric Association, 
20. These diagnoses were based on clinical assessments by a consultant psychiatrist. These details 
were not measured at the time of testing, but were taken from patient case notes and discussions with 
the treating psychiatrist. Although both groups showed low levels of anxiety and depressive 
symptomatology, the BDD group showed significantly greater severity of symptoms of depression 
(MADRS,  p=.01), and anxiety (Ham A p=.03) – see Table 2. Fifty per cent of the participants with 
BDD scored very low on the MADRS (‘normal or symptom absent’ with a MADRS score of less 
than 7 52. The majority of the remainder (n=5) scored within the ‘mild depression’ with scores 
between 7 and 19, and 1 participant scored 24 representing ‘moderate depression’ 52 
 
Table 2 about here 
 
Neurocognitive analysis. 
 
A Multivariate Analysis of Variance (MANOVA) was conducted in order to ascertain differences between the 
BDD and control groups. The MANOVA revealed significant differences between groups overall F(1,26)= 
6.89, p= .01) 
 
Table 3 about here 
 
Intra/Extra Dimensional set shift task (IED) 
The BDD group made significantly more total errors (adjusted) on the task versus controls. These 
errors were specifically seen at the extra-dimensional shift (EDS) stage (stage 8). All participants in 
both groups passed stages 1-7; however, only 50% (n=6) of the BDD group passed the EDS stage 
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while all control participants (n=16) passed the EDS stage (see Figure 1). No notable changes to the 
significance of each variable were seen when results were co-varied for anxiety and depression. 
 
 
Figure 1 about here 
 
Stop Signal Task (SST) 
The BDD group showed significantly longer stop-signal reaction times (SSRTs) than the controls. 
General psychomotor speed (measured as median ‘go’ reaction times) did not differ significantly 
between the groups. No notable changes to the significance of each variable were seen when results 
were co-varied for anxiety and depression. 
 
Cambridge Gambling Task (CGT) 
The BDD group showed significantly more delay aversion than controls. However, the BDD group 
gambled a significantly smaller proportion of total points overall. Between-group differences were 
also found in risk taking (measured by the proportion of total points bet over all trials), with the 
BDD group showing a significantly lower incidence of risk taking than controls. Groups did not 
differ significantly in terms of the proportion of rational decisions made overall. No significant 
differences were found with regard to the deliberation time when making bets. No notable changes 
to the significance of each variable were seen when results were co-varied for anxiety and 
depression.  
 
Affective Go/ No-Go (AGN) 
 
Reaction time 
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Analysis of variance showed that the BDD group were slower to respond correctly to presented 
words than the controls. Sub-analysis indicated that individuals with BDD took significantly longer 
to respond to positive words when compared to controls. The groups did not differ significantly for 
negative words. 
 
Commissions 
ANOVA showed that the number of commission errors differed significantly between the groups, 
due to higher errors in patients than controls overall. Sub-analysis indicated that there were 
significantly more commission errors in those with BDD than controls for positively and negatively 
valenced words but not neutral words. 
 
Omissions 
More non-responses (omissions) were seen in the BDD group compared with controls overall. When 
exploring emotional valence, the BDD group made statistically more omissions for positively 
valenced words, and for negatively valenced words; but not neutral words. No notable changes to the 
significance of each variable were seen when any of the AGN results were co-varied for anxiety and 
depression. 
 
Discussion 
This study contributes to the body of research documenting impaired neurocognitive performance in 
BDD. Differences were seen between individuals with and without BDD and cognitive results 
generally appeared to be unaffected by severity of mood and anxiety symptoms.  
Cognitive Inflexibility: The BDD group made significantly more errors on the IED task, with a 
significantly higher error rate at stage 8 of the task (the extra-dimensional shift stage- EDS). Only 
50% of the BDD group progressed to stage 8 (EDS). Results from the IED task indicates significant 
attentional (or cognitive) inflexibility within the BDD group. A number of studies have found 
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deficits in cognitive flexibility in OCD patients 28,35,53,54, with the deficits appearing exclusively at 
the extra-dimensional stage (EDS), as was the case in the current study. The neurobiology of 
attentional shift flexibility has been the subject of translational study. Research into rodents 55, 
primates 56-58 and humans 45,48,59 implicate the ventro-lateral prefrontal cortex (or functionally 
homologous regions) as being required for intact cognitive flexibility.  
The finding of cognitive inflexibility in the BDD group converges with published findings for 
OCD35 and with the clinical presentation of the disorder – specifically with the performance of 
compulsive (repetitive, urge-driven) behaviour. Individuals with BDD engage compulsively in 
thoughts or behaviours related to appearance and find difficulty diverting attention to non-image 
related thoughts or ‘purposeful’ forms of activity. However, we cannot exclude the possibility that 
the cognitive inflexibility found in the BDD group in this study is attributable to the presence of 
comorbid OCD, which was present in 9 of the participants.  Indeed, significant differences were seen 
for completed stage errors, when comparing the participants in the BDD group who had a diagnosis 
of OCD with those who did not, suggesting that the presence of OCD may have had an influence 
upon cognitive flexibility. This may be clinically relevant, in that people with BDD comorbid with 
OCD may have a more rigid response style, which could impede ability to adjust behaviors in day-
to-day life, and to engage with psychological treatments.  
Decision Making: The Cambridge Gambling Task (CGT) is a measure of decision-making abilities 
with the advantage of assessing different aspects of decision-making separately 60-62. Individuals 
with OCD have been found to be unimpaired on the CGT 28, though abnormal performance on the 
task versus controls can be elicited in OCD with acute serotonergic challenge (Lochner et al., 
submitted). However, our results showed abnormal decision-making in a BDD sample. A higher 
incidence of delay aversion was seen in BDD patients (i.e. participants were unwilling to wait for 
bets to increase/decrease) suggesting an increased degree of impatience (decision-making 
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impulsivity). Hollander and Wong 63, in their investigation of gambling disorder and its associations 
with BDD, found that individuals with BDD showed an increased tendency for gambling.  
Motor Impulsivity: Significant differences in motor impulsivity were found between BDD patients 
and controls on the Stop Signal Reaction Time (SSRT) task. Impaired motor response inhibition has 
been proposed to represent an endophenotype of OCD, as studies have found that unaffected 
relatives are also impaired on the SSRT 28. Performance on the SSRT is dependent on an intact right 
inferior frontal gyrus 64,65. A number of further brain areas have been implicated in impaired 
response inhibition in OCD 66 including the orbitofrontal cortex, anterior cingulate, parietal cortex, 
caudate-putamen and cerebellum, suggesting involvement of circuits within and outside the 
orbitofrontal –striatal -thalamic loop.  
Overall Impulse Control: Our data suggest that participants with BDD exhibit signs of both decision-
making impulsivity and motor impulsivity. These findings align with the clinical phenomenology; 
many of the characteristic behavioural symptoms of BDD, e.g. being unable to resist the urge to 
undertake cosmetic, and even ’do it yourself (DIY)’ surgery to ‘correct’ perceived flaws, may be 
construed as poor impulse control. Indeed Veale 67 reported that of 25 patients he interviewed, nine 
(36%) had carried out their own DIY surgery in an attempt to dramatically alter their appearance. In 
addition, suicidal acts are common in patients with BDD. A large prospective study of suicide 
showed that in 185 BDD participants followed up over 4 years, for each year spent in the study an 
average of 57.8% reported suicidal urges, 2.6% attempted suicide and 0.3% (2 people) completed 
suicide.   
While ‘impulsivity’ implies a predisposition toward performing rapid and unplanned reactions to 
stimuli and ‘compulsivity’ relates to the urge-driven performance of repetitive unwanted acts, both 
domains can be considered to represent a dysfunction in impulse control 68 and both may be 
represented in BDD. Separate cortico-striatal circuits are thought to sub-serve impulsivity (ventral) 
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and compulsivity (dorsal)23. Hyperactivity of the striatal circuit (generation of activity) and 
hypoactivity of the prefrontal circuit (inhibition) may represent a common mechanism underpinning 
impulse control deficits in a range of obsessive-compulsive disorders such as OCD and BDD23.  
Affective Processing: On the AGN task, the BDD group showed a longer reaction time between the 
presentation of a target word and a correct response i.e. they took longer to respond to the target 
word, when a correct answer was given. In addition, individuals with BDD showed a higher instance 
of errors characterised by responding to distracter stimuli (non-target words) and also a higher 
instance of non-response on target stimuli compared with controls. These data mirror previous 
findings for OCD, in which disorder inappropriate motor responses to non-target stimuli were 
observed in comparison to those seen in healthy controls 69,70. Findings in OCD studies have been 
specific for word valance, with negative words being more difficult to forget in OCD groups a 
potential suggestion of incorrect processing of negative words 71 but additional findings suggest that 
the type of word most difficult to forget in OCD groups is the type associated with their current 
OCD presentation- positive or negative 72. In the current study, individuals with BDD showed a 
longer reaction time, more errors and non-responses for positive and negative target words, but not 
neutral target words. Previous OCD research revealed elevated commission errors for neutral words, 
compared with happy and sad words, in patients in one study 73; while another study found more 
omission errors for sad target words in OCD46. One interpretation for the current results in BDD 
patients is that the disorder is associated with more generalized dysregulation of emotional 
processing circuitry, with a global untoward impact of emotional information on attentional 
processing. Thus, the presentation of emotionally valenced stimuli (whether positive or negative) 
results in performance decrements that generalize across both commission and omission errors, with 
neutral stimuli not having such a pronounced effect.  
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Also, increased errors in the BDD group to positive and negative target and distractor words could 
result from individuals with BDD being unusually sensitive to emotional cues, i.e. stimuli that have 
some meaning to the BDD disorder. These could be negative words such as ‘ugly’ or even positive 
words such as ‘attractive’. Our findings revealed differences based on word valence, and not on 
neutral word trials, suggesting that the symptoms of BDD may rely on an inherent focus on both 
negatives and positives about appearance. Additionally, this bias within the BDD condition may 
result from cognitive inflexibility, in that individuals with BDD may become ‘stuck’ in a routine of 
thinking about positive and negative aspects of themselves.  
 
The development of self - image and the role of appearance is thought to be influenced by 
environmental factors, including significant life events and shaped by memory 74-76. Individuals with 
BDD commonly report instances of bullying and teasing, potentially increasing their propensity for 
negative perception of themselves and of specific body parts 76,77. The finding of attentional bias 
toward affectively valenced words is consistent with this literature and may help explain how such 
experiences become overvalued and may result in an obsessive preoccupation with body image. Few 
studies have tested attention in BDD. Our findings suggest future research investigating the effect of 
BDD on attention to environmental cues, and the consequent impact on psychosocial function, is 
desirable. 
 
Limitations: Our modest BDD sample may have had reduced statistical power to detect other 
potential differences of relevance. Other BDD studies of this type have also reported a small sample 
size and it may be that recruitment to BDD studies is particularly challenging (anecdotally, our 
perception was that BDD patients seemed reluctant to engage in research that focused attention on 
themselves). Nonetheless, replication in larger samples is required. OCD and affective comorbidity 
could have had a confounding influence on the findings, considering 75% of our BDD group had 
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comorbid OCD and 50% comorbid depressive symptomatology. On the other hand, the BDD cases 
were drawn from a well-defined clinical cohort, BDD was recognised by the patients and their 
clinicians as the primary disorder and constituted the focus for clinical treatment. BDD in clinical 
cohorts is almost always comorbid with disorders such as OCD and depression 10,78 and by including 
patients with relevant comorbidity, the results may be generalised to BDD patients seen in the 
clinical setting. While the relatively low magnitude of BDD-YBOCS scores in some of the BDD 
group participants may pose a limitation in clearly differentiating groups, this finding may be 
attributed to the effect of clinical treatment. This, in itself, does not invalidate our findings and may 
relate to trait, rather than state, illness. A clinical control was not used as a comparison to the BDD 
and healthy control groups. In future studies, it would be beneficial to compare those with a 
diagnosis of BDD with an OCD control group in order to further investigate cognitive correlates 
between these two clinical presentations and potentially further support the presence of BDD on the 
obsessive compulsive spectrum. Additional benefit would be gained from performing a full 
structured diagnostic screen on participants in order to gain a better picture of overall illness profile, 
or absence of illness. 
Recognition of the influence that medication may have had on potentially changing the 
neurocognitive performance of BDD participants should be noted as all 12 of the BDD participants 
were taking medication (2 citalopram, 6 escitalopram, 3 fluvoxamine and 1 sertraline) at the time of 
testing. Certainly serotonin is known to play an important role in decision-making and emotional 
processing. Future research could be extended to investigate unaffected relatives, so as to avoid 
potential medication-related confounds. Research should also explore the functional impact of 
specific aspects of cognitive impairment on daily life, treatment-adherence, and suicidal activity.  
 
Conclusion 
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Patients with BDD were impaired compared to healthy controls on tests of cognitive flexibility, 
reward and motor impulsivity and affective processing. Results from previous studies in the OCD 
population show similar deficits in cognitive flexibility and motor impulsivity; therefore our findings 
are consistent with the re-classification of BDD with OCD.  However, the current study suggests that 
BDD may be characterized by additional abnormalities in domains of decision-making and 
emotional processing that differ from previous findings in OCD. While the study used a modest 
sample size and comorbid OCD may confound results, future work should explore the impact of 
these abnormalities on everyday functioning, ability to engage successfully with treatment and 
suicidality.  
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Tables & Figures 
 
Table 1.  Demographic analysis; BDD and control groups 
 
 
 
 
 
 
 
 
 
Table 2. Clinical measures  
Variable 
BDD (n=12) Control (n=16)   
Mean SD Mean SD     F p  
Age (years) 30.08 (8.92) 35.80 (12.10) 1.87 .18  
Education (years) 14.08 (1.88) 14.41 (1.99) 0.23 .64  
NART (IQ) 113.80 (2.95) 115.00 (3.34) 0.22 .64  
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Note: HAM-A: Hamilton Anxiety Scale, MADRS: Montgomery-Åsberg Depression Rating Scale, 
BDD-YBOCS: Yale Brown Obsessive Compulsive Scale for Body Dysmorphic Disorder 
 
 
 
 
  
 BDD (n=12) Control (n=16)  
Mean SD Mean SD F p 
HAM-A 8.08 (6.75) 3.94 (3.04) 4.76 .03* 
MADRS 7.50 (5.98) 2.50 (4.29) 6.66 .01* 
BDD-YBOCS 13.25 (4.88) 2.38 (3.40) 48.40 <.001* 
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Table 3. Neurocognitive test performance 
  BDD Control  
  Mean SD Mean SD F p Cohen’s d 
IED   Stages completed 8.00 1.04 8.94 .25 8.87 .007* 1.21 
  Total Errors 26.75 10.95 13.18 4.98 13.00 .001* 1.47 
EDS Errors 17.25 12.10 4.75 3.92 10.56 .003* 1.32 
CGT  Delay Aversion .47 .17 .28 .19 5.22 .03* 0.94 
  Deliberation Time (msec) 1827.05 741.28 2133.09 533.32 1.84 .20* 0.55 
Overall proportion of bet .50 .05 .76 .09 63.16 <.001* 3.24 
Risk taking .56 .06 .69 .14 1.68 .04* 1.25 
Quality of DM .89 .15 .87 .24 .45 .51 0.27 
SST   Mean Reaction Time  477.19 130.99 465.57 76.36 .02 .90 0.00 
  Stop Signal Reaction Time 182.64 74.84 137.81 52.62 4.66 .04* 0.87 
AGN Mean Correct Latency 535.00 82.31 473.22 60.78 4.85 .03* 0.90 
               POSITIVE 545.46 90.80 418.74 49.73 19.76 <.001* 1.81 
  
 
Total Omissions 6.92 3.40 1.19 1.64 24.44 <.001* 2.00 
              POSITIVE 1.33 1.37 .13 .34 7.11 .01*   1.09 
              NEGATIVE 1.66 1.49 .19 .40 10.90 .003* 1.34 
               NEUTRAL .00 .00 .06 .25 .26 .61 0.20 
Total Commissions 10.17 7.66 4.62 2.09 5.86 .02* 0.96 
                POSITIVE 3.75 3.13 .75 .85 10.78 .003* 1.34 
              NEGATIVE 2.16 1.69 1.12 .72 3.74 .06 0.79 
                 NEUTRAL .19 .54 .10 .42 .50 .49 0.29 
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Note:  * denotes a statistically significant result. IED (Intra/Extra Dimensional shift task), CGT (Cambridge 
Gambling Task), SST (Stop Signal Task), AGN (Affective Go/NoGo task) 
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Figure 1. Percentage of BDD and control participants passing each stage on the IDED task 
Note: SD = simple discrimination; SR = simple reversal; CDA = compound discrimination adjacent; CDS = compound 
discrimination superimposed; CR = compound reversal; ids = intra-dimensional shift; IDSR = intra-dimensional shift 
reversal; EDS = extra-dimensional shift; EDSR = extra-dimensional shift reversal 
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